| Sun Nan,Sun Xianglu,Liu Jing,et al.Value of radiotherapy in metastatic HER2-overexpressing breast cancer treated with pyrotinib[J].Chinese Journal of Radiological Medicine and Protection,2025,45(3):183-187 |
| Value of radiotherapy in metastatic HER2-overexpressing breast cancer treated with pyrotinib |
| Received:April 12, 2024 |
| DOI：10.3760/cma.j.cn112271-20240412-00131 |
| KeyWords:Metastatic breast cancer Human epidermal growth factor receptor 2 Radiotherapy Pyrotinib |
| FundProject:安徽高校自然科学研究重点项目(2023AH051978);蚌埠医学院第一附属医院高水平科技创新团队基金(BYYFY2022TD003) |
| Author Name | Affiliation | E-mail | | Sun Nan | Department of Radiation Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, China | | | Sun Xianglu | Department of Radiation Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, China | | | Liu Jing | Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, China | | | Yang Yan | Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, China | | | Zhou Yongchun | Department of Radiation Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu 233000, China
Anhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, Bengbu Medical University, Bengbu 233000, China | zhouyongchun@bbmu.edu.cn |
|
| Hits: 2492 |
| Download times: 1008 |
| Abstract:: |
| Objective To investigate the efficacy of radiotherapy in postoperative metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treated with pyrotinib, and to identify potential subgroups that may benefit from this strategy. Methods The clinical data of 187 patients with postoperative distant metastatic HER2-overexpressing breast cancer who received pyrotinib at the First Affiliated Hospital of Bengbu Medical University from January 2018 to July 2022 were retrospectively analyzed. The Kaplan-Meier method was used to assess changes in survival outcomes in patients undergoing radiotherapy. Univariate and multivariate analyses were conducted to identify prognostic factors, and the log-rank test was used to determine potential subgroups that may benefit from radiotherapy. Results Among the 187 patients, 76 received radiotherapy. The median follow-up duration for the entire population was 16.9 months (range: 3.1-37.9 months), and the 2-year overall survival (OS) was 75.0%. Multivariate analysis showed that age, metastatic status, and radiotherapy were independent factors affecting OS (3.86-6.76, P< 0.05). Further subgroup analysis showed that radiotherapy significantly improved OS in patients aged ≥50 years, those with oligometastases or bone metastases, those not receiving endocrine therapy, and those resistant to trastuzumab (P< 0.05). Conclusions Radiotherapy, in addition to pyrotinib, can enhance the survival rate of patients with postoperative metastatic HER2-overexpressing breast cancer. The benefits of radiotherapy may be more pronounced in patients with a low tumor burden, inadequate systemic treatment, and drug resistance. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
